At ASRS 2025, Everads to Deliver Two Oral Presentations Highlighting Complete Clinical Trial Results of Its Innovative Suprachoroidal Injector
Everads Therapy, a clinical-stage company based in Israel, is making strides in the field of retinal disease treatment. Specialising in a unique suprachoroidal delivery technology, Everads Therapy is poised to revolutionise the way retinal diseases are treated.
The company's platform is designed for rapid, broad, and safe drug distribution in the suprachoroidal space, making it possible for treatments to be administered in an office-based setting via a non-surgical, minimally invasive injection. This approach could significantly improve patient care and reduce the need for complex surgical procedures.
Everads Therapy's core technologies are licensed from the laboratory of Prof Y Rotenstreich at the Sheba Tel Hashomer Medical Center / Sheba Impact. The company was established within RAD Biomed, a premier biotech accelerator, and was founded as a spin-off from DALI Medical Devices, a leader in injectable drug delivery technologies.
Moshe Weinstein serves as the Executive Chairman of Everads Therapy. Under his leadership, the company has collaborated with partners across gene therapy, cell therapy, small molecule formulations, and other modalities to realise the full potential of its differentiated delivery approach.
Recently, Everads Therapy announced two oral presentations at the 2025 ASRS Annual Meeting. One presentation includes full results from Everads Therapy's first-in-human clinical trial, while the other presents the preclinical study confirming the usability of the Everads Injector for minimally invasive suprachoroidal buckling to treat retinal detachment.
The preclinical study was conducted by the research group led by Professor Thomas A. L. J. S. M. V. G. (the specific research group name or leader was not provided). Gareth D. Mercer, MD, PhD, and colleagues also contributed to this study.
The clinical trial (NCT06314217) evaluated the safety and performance of the Everads Injector for suprachoroidal administration of a triamcinolone acetonide suspension in patients with diabetic macular edema. Results demonstrated the safety, feasibility, and ease of use of the injector in an office-based setting.
Moreover, the preclinical study also showed a predictable, linear relationship between injection volume and buckle size. A preclinical study using human cadaver eyes demonstrated that the Everads Injector can reliably deliver viscoelastic into the suprachoroidal space, producing consistent buckles.
Everads Therapy is also developing this platform for in-office suprachoroidal buckling (viscopexy) to treat select retinal detachments. Yoreh Barak, MD, the Head of Retina at Rambam Medical Center, serves as the Principal Investigator of Everads Therapy's clinical study.
For more information about Everads Therapy and its innovative work, please visit www.everads-therapy.com and follow the company on LinkedIn.
Read also:
- Overweight women undergoing IVF have a 47% higher chance of conceiving naturally post-weight loss
- Bonsai Trees from Evergreen Species: Exploring Growth Characteristics & Distinct Qualities
- What temperatures may make walking your canine companion uncomfortable?
- Title: Information About Beovu: Potency, Form, Usage, and Additional Details
